By Ana Mano and Luciana Magalhaes SAO PAULO (Reuters) - JBS SA, the world's largest meat-packer, appears to have moved a step closer to obtaining the necessary approvals for a primary listing of shares on the New York Stock Exchange, according to a regulatory document filed with the U.S. market regulator. The U.S. listing, which has been in the works for years, would provide access to a broader pool of investors and possibly aid JBS, which is now primarily listed in Brazil, in raising its valuation closer to its industry peers. In the filing, issued on Friday, JBS projects that its board of directors could convene as early as April 22 to call a general meeting of JBS shareholders, who are required to decide on whether they approve of the company's "dual listing" plan. The general shareholders meeting could be held around May 23 and the first day of trading of JBS shares in New York could be around June 12, according to the filing that the company sent to the Securities and Exchange Commission (SEC). Igor Guedes, an equity analyst at Genial Investimentos, said the tentative dates seem to be "a good sign" that suggest that JBS may be optimistic about the timing of its U.S. listing. He noted, however, that the schedule isn't entirely under the company's control. A source familiar with JBS' U.S. listing procedures said the SEC had requested the company to estimate possible dates to turn in the F-4 filing used to register securities by foreign private issuers, noting that they are currently tentative and subject to change. "The JBS S.A. General Meeting tentatively scheduled for May 23, 2025 will not be called if the registration statement on Form F-4 of which this prospectus is a part is not declared effective," the company said in the regulatory filing, noting that the meat-packer still needs the approval from the U.S. regulator to move forward with its plan. With the dual listing, JBS stocks would trade both in the U.S. and in Brazil, where it will issue Brazilian depositary receipts. Last month, the second largest shareholder of JBS, the equity arm of Brazil's development bank BNDESPar, said it would abstain from voting at the upcoming shareholders meeting. The announcement boosted JBS' share price because there was uncertainty about whether BNDESPar would endorse JBS' U.S. listing strategy. JBS declined to comment. The SEC did not immediately respond to a request for comment. (Reporting by Ana Mano and Luciana Magalhães in São Paulo; Editing by Aurora Ellis)
JBS sets tentative dates for US listing vote, share trading in NY
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...